{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T16:26:37Z","timestamp":1776270397582,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T00:00:00Z","timestamp":1731283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T00:00:00Z","timestamp":1731283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NYU Langone TULA Health Research Fellowship"},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R25DA033211"],"award-info":[{"award-number":["R25DA033211"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000102","name":"Health Resources and Services Administration","doi-asserted-by":"publisher","award":["T25HP37605"],"award-info":[{"award-number":["T25HP37605"]}],"id":[{"id":"10.13039\/100000102","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Anabolic androgenic steroids (AAS) are synthetic forms of testosterone frequently used as performance enhancing drugs among gay, bisexual, and queer (GBQ) men. Despite widespread use, associated harms, and the likely existence of an AAS use disorder, there is no medical consensus on standards of care for people who use AAS, with most medical providers focusing exclusively on abstinence. Individuals using AAS have developed community-based harm reduction strategies to mitigate these harms.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This paper is a sub-analysis of qualitative data obtained through semi-structured interviews with GBQ men using AAS for 8 or more weeks recruited through convenience and snowball sampling from clinical sites and LGBTQ\u2009+\u2009venues in New York City as well as through social media. Interviews were coded with themes developed using reflexive thematic analysis. Data related to harm reduction techniques were then re-analyzed through a prevention strategies framework lens of primary, secondary, and tertiary harm prevention.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Thematic saturation was reached at twelve interviews in the primary analysis, with men reporting frequent use of multiple harm reduction techniques. For primary prevention, men avoided oral steroids and simultaneous substance use, tried to obtain AAS from reputable sources, used \u201ccycling\u201d to dose steroids, and practiced sterile injection techniques. Secondary prevention methods included patient-directed lab testing for hematocrit, liver and kidney function, cholesterol, prostate specific antigen, testosterone, and self-performed blood pressure checks. Tertiary prevention included donating blood and the use of medications without a prescription, including aromatase inhibitors, selective estrogen receptor blockers, aspirin, statins, angiotensin receptor blockers, clomiphene, and human chorionic gonadotropin.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Despite many GBQ men experiencing harms from anabolic androgenic steroids, community members have often sought harm reduction techniques in lieu of abstinence. Though many of these techniques embrace clinical reasoning and may be more broadly applicable, additional research is needed to understand the impact of each intervention on the overall health of individuals using AAS.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12954-024-01121-8","type":"journal-article","created":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T02:11:11Z","timestamp":1731291071000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Harm reduction techniques among cisgender gay, bisexual, and queer men using anabolic androgenic steroids: a qualitative study"],"prefix":"10.1186","volume":"21","author":[{"given":"Eric","family":"Kutscher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arslaan","family":"Arshed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard E.","family":"Greene","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mat","family":"Kladney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,11]]},"reference":[{"issue":"4","key":"1121_CR1","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/j.1521-0391.2013.12118.x","volume":"23","author":"HG Pope","year":"2014","unstructured":"Pope HG, Kanayama G, Athey A, Ryan E, Hudson JI, Baggish A. The lifetime prevalence of anabolic-androgenic steroid use and dependence in americans: current best estimates. Am J Addict Am Acad Psychiatr Alcohol Addict. 2014;23(4):371\u20137. https:\/\/doi.org\/10.1111\/j.1521-0391.2013.12118.x.","journal-title":"Am J Addict Am Acad Psychiatr Alcohol Addict"},{"issue":"1","key":"1121_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJM199607043350101","volume":"335","author":"S Bhasin","year":"1996","unstructured":"Bhasin S, Storer TW, Berman N, et al. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med. 1996;335(1):1\u20137. https:\/\/doi.org\/10.1056\/NEJM199607043350101.","journal-title":"N Engl J Med"},{"issue":"3","key":"1121_CR3","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1542\/peds.2013-2768","volume":"133","author":"AJ Blashill","year":"2014","unstructured":"Blashill AJ, Safren SA. Sexual orientation and anabolic-androgenic steroids in us adolescent boys. Pediatrics. 2014;133(3):469\u201375. https:\/\/doi.org\/10.1542\/peds.2013-2768.","journal-title":"Pediatrics"},{"issue":"2","key":"1121_CR4","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1037\/1524-9220.9.2.106","volume":"9","author":"PN Halkitis","year":"2008","unstructured":"Halkitis PN, Moeller RW, DeRaleau LB. Steroid use in gay, bisexual, and nonidentified men-who-have-sex-with-men: relations to masculinity, physical, and mental health. Psychol Men Masc. 2008;9(2):106\u201315. https:\/\/doi.org\/10.1037\/1524-9220.9.2.106.","journal-title":"Psychol Men Masc"},{"issue":"2","key":"1121_CR5","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/ajad.12865","volume":"28","author":"EJ Ip","year":"2019","unstructured":"Ip EJ, Doroudgar S, Shah-Manek B, et al. The CASTRO study: unsafe sexual behaviors and illicit drug use among gay and bisexual men who use anabolic steroids. Am J Addict. 2019;28(2):101\u201310. https:\/\/doi.org\/10.1111\/ajad.12865.","journal-title":"Am J Addict"},{"issue":"2","key":"1121_CR6","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1159\/000528256","volume":"29","author":"TI de Zeeuw","year":"2023","unstructured":"de Zeeuw TI, Brunt TM, van Amsterdam J, van de Ven K, van den Brink W. Anabolic androgenic steroid use patterns and Steroid use disorders in a sample of male gym visitors. Eur Addict Res. 2023;29(2):99\u2013108. https:\/\/doi.org\/10.1159\/000528256.","journal-title":"Eur Addict Res"},{"issue":"12","key":"1121_CR7","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1111\/j.1360-0443.2009.02734.x","volume":"104","author":"G Kanayama","year":"2009","unstructured":"Kanayama G, Brower KJ, Wood RI, Hudson JI Jr, HGP. Anabolic\u2013androgenic steroid dependence: an emerging disorder. Addiction. 2009;104(12):1966\u201378. https:\/\/doi.org\/10.1111\/j.1360-0443.2009.02734.x.","journal-title":"Addiction"},{"issue":"22","key":"1121_CR8","doi-asserted-by":"publisher","first-page":"3166","DOI":"10.1001\/jama.1989.03430220089036","volume":"262","author":"KB Kashkin","year":"1989","unstructured":"Kashkin KB, Kleber HD. Hooked on hormones?: an anabolic steroid addiction hypothesis. JAMA. 1989;262(22):3166\u201370. https:\/\/doi.org\/10.1001\/jama.1989.03430220089036.","journal-title":"JAMA"},{"issue":"5","key":"1121_CR9","doi-asserted-by":"publisher","first-page":"e2411088","DOI":"10.1001\/jamanetworkopen.2024.11088","volume":"7","author":"E Kutscher","year":"2024","unstructured":"Kutscher E, Arshed A, Greene RE, Kladney M. Exploring anabolic androgenic steroid use among cisgender gay, bisexual, and queer men. JAMA Netw Open. 2024;7(5):e2411088. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.11088.","journal-title":"JAMA Netw Open"},{"issue":"3","key":"1121_CR10","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1210\/er.2013-1058","volume":"35","author":"HG Pope Jr","year":"2014","unstructured":"Pope HG Jr, Wood RI, Rogol A, Nyberg F, Bowers L, Bhasin S. Adverse health consequences of performance-enhancing drugs: an endocrine society scientific statement. Endocr Rev. 2014;35(3):341\u201375. https:\/\/doi.org\/10.1210\/er.2013-1058.","journal-title":"Endocr Rev"},{"issue":"1\u20132","key":"1121_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drugalcdep.2008.05.004","volume":"98","author":"G Kanayama","year":"2008","unstructured":"Kanayama G, Hudson JI, Pope HG. Long-term psychiatric and medical consequences of anabolic-androgenic steroid abuse: a looming public health concern? Drug Alcohol Depend. 2008;98(1\u20132):1\u201312. https:\/\/doi.org\/10.1016\/j.drugalcdep.2008.05.004.","journal-title":"Drug Alcohol Depend"},{"issue":"14","key":"1121_CR12","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1001\/jama.2024.3180","volume":"331","author":"J Windfeld-Mathiasen","year":"2024","unstructured":"Windfeld-Mathiasen J, Heerfordt IM, Dalhoff KP, Andersen JT, Horwitz H. Mortality among users of anabolic steroids. JAMA. 2024;331(14):1229\u201330. https:\/\/doi.org\/10.1001\/jama.2024.3180.","journal-title":"JAMA"},{"key":"1121_CR13","doi-asserted-by":"publisher","unstructured":"Dunn M, Dawe J, Eu B, Lee K, Piatkowski T, Stoov\u00e9 M. The health effects of non-prescribed anabolic-androgenic steroid use: Findings from The Performance and image-enhancing drugs UseRS\u2019 Health (PUSH) audit. Drug Alcohol Rev. Published online July 7, 2024. https:\/\/doi.org\/10.1111\/dar.13899","DOI":"10.1111\/dar.13899"},{"issue":"7","key":"1121_CR14","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1080\/10826084.2016.1267224","volume":"52","author":"EJ Ip","year":"2017","unstructured":"Ip EJ, Yadao MA, Shah BM, et al. Polypharmacy, infectious diseases, sexual behavior, and psychophysical health among anabolic steroid-using homosexual and heterosexual gym patrons in San Francisco\u2019s castro district. Subst Use Misuse. 2017;52(7):959\u201368. https:\/\/doi.org\/10.1080\/10826084.2016.1267224.","journal-title":"Subst Use Misuse"},{"issue":"4","key":"1121_CR15","doi-asserted-by":"publisher","first-page":"100267","DOI":"10.1016\/j.peh.2023.100267","volume":"11","author":"J Amaral","year":"2023","unstructured":"Amaral J, Kimerg\u00e5rd A, Deluca P. Preventing and treating the adverse health conditions of androgenic-anabolic steroids: an online survey with 883 users in the United Kingdom. Perform Enhanc Health. 2023;11(4):100267. https:\/\/doi.org\/10.1016\/j.peh.2023.100267.","journal-title":"Perform Enhanc Health"},{"issue":"3","key":"1121_CR16","doi-asserted-by":"publisher","first-page":"100223","DOI":"10.1016\/j.peh.2022.100223","volume":"10","author":"TM Piatkowski","year":"2022","unstructured":"Piatkowski TM, Hides LM, White KM, Obst PL, Dunn M. Understanding harm reduction perspectives of performance and image enhancing drug consumers and health care providers. Perform Enhanc Health. 2022;10(3):100223. https:\/\/doi.org\/10.1016\/j.peh.2022.100223.","journal-title":"Perform Enhanc Health"},{"issue":"2","key":"1121_CR17","doi-asserted-by":"publisher","first-page":"100247","DOI":"10.1016\/j.peh.2023.100247","volume":"11","author":"M Dunn","year":"2023","unstructured":"Dunn M, Piatkowski T, Whiteside B, Eu B. Exploring the experiences of general practitioners working with patients who use performance and image enhancing drugs. Perform Enhanc Health. 2023;11(2):100247. https:\/\/doi.org\/10.1016\/j.peh.2023.100247.","journal-title":"Perform Enhanc Health"},{"issue":"1","key":"1121_CR18","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12954-019-0343-1","volume":"16","author":"G Bates","year":"2019","unstructured":"Bates G, Van Hout MC, Teck JTW, McVeigh J. Treatments for people who use anabolic androgenic steroids: a scoping review. Harm Reduct J. 2019;16(1):75. https:\/\/doi.org\/10.1186\/s12954-019-0343-1.","journal-title":"Harm Reduct J"},{"issue":"1","key":"1121_CR19","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1186\/s12889-019-7288-x","volume":"19","author":"O Harvey","year":"2019","unstructured":"Harvey O, Keen S, Parrish M, van Teijlingen E. Support for people who use anabolic androgenic steroids: a systematic scoping review into what they want and what they access. BMC Public Health. 2019;19(1):1024. https:\/\/doi.org\/10.1186\/s12889-019-7288-x.","journal-title":"BMC Public Health"},{"issue":"6","key":"1121_CR20","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1097\/MED.0000000000000676","volume":"28","author":"G Bates","year":"2021","unstructured":"Bates G, Shepherd S, McVeigh J. Harm reduction strategies for androgen users: providing appropriate support and improving engagement with healthcare. Curr Opin Endocrinol Diabetes Obes. 2021;28(6):630. https:\/\/doi.org\/10.1097\/MED.0000000000000676.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"4","key":"1121_CR21","doi-asserted-by":"publisher","first-page":"100288","DOI":"10.1016\/j.peh.2024.100288","volume":"12","author":"DL Smit","year":"2024","unstructured":"Smit DL, Verdegaal T, Bond P, de Ronde W. Navigating non-medical androgen use: towards a harm reduction paradigm. Perform Enhanc Health. 2024;12(4):100288. https:\/\/doi.org\/10.1016\/j.peh.2024.100288.","journal-title":"Perform Enhanc Health"},{"key":"1121_CR22","doi-asserted-by":"publisher","first-page":"i1889","DOI":"10.1136\/bmj.i1889","volume":"353","author":"J McVeigh","year":"2016","unstructured":"McVeigh J, Kimerg\u00e5rd A, Bates G, Hope VD, Ncube F. Harm reduction interventions should encompass people who inject image and performance enhancing drugs. BMJ. 2016;353:i1889. https:\/\/doi.org\/10.1136\/bmj.i1889.","journal-title":"BMJ"},{"key":"1121_CR23","unstructured":"Kisling LA, Das JM. Prevention Strategies. In: StatPearls. StatPearls Publishing; 2024. Accessed July 28, 2024. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK537222\/"},{"key":"1121_CR24","doi-asserted-by":"publisher","unstructured":"Latimore AD, Afshar ES, Duff N, et al. Primary, Secondary, and Tertiary Prevention of Substance Use Disorders through Socioecological Strategies. NAM Perspect. Published online September 6, 2023. https:\/\/doi.org\/10.31478\/202309b","DOI":"10.31478\/202309b"},{"issue":"6","key":"1121_CR25","doi-asserted-by":"publisher","first-page":"e397","DOI":"10.1016\/S2468-2667(24)00031-8","volume":"9","author":"A Ishizumi","year":"2024","unstructured":"Ishizumi A, Kolis J, Abad N, et al. Beyond misinformation: developing a public health prevention framework for managing information ecosystems. Lancet Public Health. 2024;9(6):e397\u2013406. https:\/\/doi.org\/10.1016\/S2468-2667(24)00031-8.","journal-title":"Lancet Public Health"},{"key":"1121_CR26","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1146\/annurev-publhealth-031914-122957","volume":"36","author":"A Kolodny","year":"2015","unstructured":"Kolodny A, Courtwright DT, Hwang CS, et al. The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction. Annu Rev Public Health. 2015;36:559\u201374. https:\/\/doi.org\/10.1146\/annurev-publhealth-031914-122957.","journal-title":"Annu Rev Public Health"},{"issue":"1","key":"1121_CR27","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12954-017-0176-8","volume":"14","author":"B Tighe","year":"2017","unstructured":"Tighe B, Dunn M, McKay FH, Piatkowski T. Information sought, information shared: exploring performance and image enhancing drug user-facilitated harm reduction information in online forums. Harm Reduct J. 2017;14(1):48. https:\/\/doi.org\/10.1186\/s12954-017-0176-8.","journal-title":"Harm Reduct J"},{"key":"1121_CR28","doi-asserted-by":"publisher","unstructured":"Piatkowski T, Cox L, Gibbs N, Turnock L, Dunn M. \u2018The general concept is a safer use approach\u2019: how image and performance enhancing drug coaches negotiate safety through community care. Drugs Educ Prev Policy.:1\u20139. https:\/\/doi.org\/10.1080\/09687637.2024.2352442","DOI":"10.1080\/09687637.2024.2352442"},{"issue":"9","key":"1121_CR29","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1111\/j.1360-0443.2004.00781.x","volume":"99","author":"HG Pope","year":"2004","unstructured":"Pope HG, Kanayama G, Ionescu-Pioggia M, Hudson JI. Anabolic steroid users\u2019 attitudes towards physicians. Addiction. 2004;99(9):1189\u201394. https:\/\/doi.org\/10.1111\/j.1360-0443.2004.00781.x.","journal-title":"Addiction"},{"issue":"1","key":"1121_CR30","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13011-023-00573-8","volume":"18","author":"B Grant","year":"2023","unstructured":"Grant B, Kean J, Vali N, et al. The use of post-cycle therapy is associated with reduced withdrawal symptoms from anabolic-androgenic steroid use: a survey of 470 men. Subst Abuse Treat Prev Policy. 2023;18(1):66. https:\/\/doi.org\/10.1186\/s13011-023-00573-8.","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"1","key":"1121_CR31","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1477-7517-11-19","volume":"11","author":"A Kimerg\u00e5rd","year":"2014","unstructured":"Kimerg\u00e5rd A, McVeigh J. Variability and dilemmas in harm reduction for anabolic steroid users in the UK: a multi-area interview study. Harm Reduct J. 2014;11(1):19. https:\/\/doi.org\/10.1186\/1477-7517-11-19.","journal-title":"Harm Reduct J"},{"issue":"1","key":"1121_CR32","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1017\/S0950268814000727","volume":"143","author":"VD Hope","year":"2015","unstructured":"Hope VD, McVEIGH J, Marongiu A, et al. Injection site infections and injuries in men who inject image- and performance-enhancing drugs: prevalence, risks factors, and healthcare seeking. Epidemiol Infect. 2015;143(1):132\u201340. https:\/\/doi.org\/10.1017\/S0950268814000727.","journal-title":"Epidemiol Infect"},{"issue":"12","key":"1121_CR33","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1046\/j.1360-0443.1999.941218298.x","volume":"94","author":"G Bolding","year":"1999","unstructured":"Bolding G, Sherr L, Maguire M, Elford J. HIV risk behaviours among gay men who use anabolic steroids. Addict Abingdon Engl. 1999;94(12):1829\u201335. https:\/\/doi.org\/10.1046\/j.1360-0443.1999.941218298.x.","journal-title":"Addict Abingdon Engl"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-024-01121-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-024-01121-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-024-01121-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T15:06:49Z","timestamp":1731337609000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-024-01121-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,11]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1121"],"URL":"https:\/\/doi.org\/10.1186\/s12954-024-01121-8","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,11]]},"assertion":[{"value":"11 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"196"}}